TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05282212

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Scan
Description: Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
Study: NCT05446948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: beveled 27G+ vitrectomy system
Description: The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 25G+ vitrectomy system
Description: The device is a traditional instrument, and its probe tip is flat.
Study: NCT05703438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritionally balanced low-calorie diet
Description: Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
Study: NCT06406153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipyretic
Description: An antipyretic is administered one hour before the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: An antipyretic is administered one hour before the infusion.
Study: NCT06171932

Intervention type: DRUG
Intervention: Methylprednisolone,
Description: No intervention required
Study: NCT06649149

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
Study: NCT06649006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: IV infusion
Study: NCT05022485

Intervention type: DEVICE
Intervention: ZNN Bactiguard tibia
Description: Tibia fracture fixation
Study: NCT05096663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cobalamin
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given orally (PO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nogapendekin Alfa
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study: NCT06078150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video games intervention（1-6weeks）
Description: Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video games intervention（7-12weeks）
Description: Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time.
Study: NCT05580536

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project Dulce + Dulce Digital
Description: Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic.~The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes.~The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. .~Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic.
Study: NCT03068832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine
Description: -It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * After trial enrollment and up to 7 days after the 1st vaccine dose~* 2 weeks after last dose~* Time of progression or discontinuation
Study: NCT06506695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Craniofacial implant placement
Description: * Resection of oncologic process or remnants after trauma if necessary~* Placement of craniofacial implants in the nasal floor and/or the temporal bone.~* Placement of split thickness skin graft around the implants~* Placement of nose and/or ear prosthesis within 3 weeks
Study: NCT05953532

Intervention type: OTHER
Group type: OTHER
Intervention: A1Control
Description: diabetes self-management and diabetes technology education software
Study: NCT05707741

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmetomedine infusion
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmetomedine infusion
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmetomedine infusion
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmetomedine infusion
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomedine infusion
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomedine infusion
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
Study: NCT06558253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme I for Injection
Description: Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
Study: NCT06278168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Awareness training with using Oculus.
Description: The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest.

Intervention type: OTHER
Group type: OTHER
Intervention: Awareness training without using Oculus
Description: The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
Study: NCT06159036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial Strength training
Description: Low speed strength training with classic movements, derived from Olympic lifting and jumping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inertial Strength training
Description: Low speed strength training with classic movements, derived from Olympic lifting and jumping
Study: NCT06056830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
Study: NCT04877054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Treatment Program
Description: 4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
Study: NCT06641323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozonized gel
Description: Administration of Ozonized Gel GeliO3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ozonized water
Description: Admininstration of Gaseous ozone (Healozone X4)
Study: NCT06146335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kono-S anastomosis (KSa)
Description: antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Side-to-side anastomosis (SSa)
Description: side-to-side anastomosis connecting small intestine and colon after surgery
Study: NCT05039554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valera Smartphone Application
Description: For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valera Smartphone Application
Description: For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
Study: NCT04877054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
Study: NCT06435507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (50 mg)
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (100 mg)
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (200 mg)
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (400 mg)
Description: Single dose
Study: NCT05666154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real diet
Description: Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham diet
Description: Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat exclusion diet
Description: Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy exclusion diet
Description: Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study: NCT06235996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office-based procedure indicated for chronic pain with music
Description: Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office-based procedure indicated for chronic pain without music
Description: Office-based procedure indicated for chronic pain without music
Study: NCT06518629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with low power laser
Description: All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with low power laser
Description: All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation with low power laser
Description: All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
Study: NCT05679882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masking Sounds
Description: Masking sounds will be played from outdoor speakers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Masking Sounds
Description: No masking sounds will be played from outdoor speakers.
Study: NCT06387056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240mg by mouth once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240mg by mouth once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240mg by mouth once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240mg by mouth once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Microspheres for Injection
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Microspheres for Injection
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Microspheres for Injection
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Microspheres for Injection
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60mg by mouth twice a day for 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study: NCT05738863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency rTMS Protocol
Description: It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions.
Study: NCT06214728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel application
Description: HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel application
Description: The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.